Kanak V. Kennedy MD , Anna Costello MD , Melissa A. Lerman MD, PhD , Jon M. Burnham MD , Aoife Corcoran MD , Joseph Piccione DO , Alexandra Grier MD, PhD , Kathleen Sullivan MD, PhD , Terri Whitehorn-Brown MD , Caitlin J. Alexander MD , Laura S. Finn MD , Benjamin J. Wilkins MD, PhD , Amanda B. Muir MD
{"title":"治疗嗜酸性粒细胞食管炎的双鲁单抗诱发肉芽肿性高炎性状态。","authors":"Kanak V. Kennedy MD , Anna Costello MD , Melissa A. Lerman MD, PhD , Jon M. Burnham MD , Aoife Corcoran MD , Joseph Piccione DO , Alexandra Grier MD, PhD , Kathleen Sullivan MD, PhD , Terri Whitehorn-Brown MD , Caitlin J. Alexander MD , Laura S. Finn MD , Benjamin J. Wilkins MD, PhD , Amanda B. Muir MD","doi":"10.1016/j.jacig.2024.100314","DOIUrl":null,"url":null,"abstract":"<div><p>We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.</p></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100314"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001103/pdfft?md5=511687d188c2e37b4f58375efad84610&pid=1-s2.0-S2772829324001103-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis\",\"authors\":\"Kanak V. Kennedy MD , Anna Costello MD , Melissa A. Lerman MD, PhD , Jon M. Burnham MD , Aoife Corcoran MD , Joseph Piccione DO , Alexandra Grier MD, PhD , Kathleen Sullivan MD, PhD , Terri Whitehorn-Brown MD , Caitlin J. Alexander MD , Laura S. Finn MD , Benjamin J. Wilkins MD, PhD , Amanda B. Muir MD\",\"doi\":\"10.1016/j.jacig.2024.100314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.</p></div>\",\"PeriodicalId\":75041,\"journal\":{\"name\":\"The journal of allergy and clinical immunology. Global\",\"volume\":\"3 4\",\"pages\":\"Article 100314\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772829324001103/pdfft?md5=511687d188c2e37b4f58375efad84610&pid=1-s2.0-S2772829324001103-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of allergy and clinical immunology. Global\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772829324001103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of allergy and clinical immunology. Global","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772829324001103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis
We present the first case of a dupilumab-induced hyperinflammatory state in the setting of underlying eosinophilic esophagitis characterized by multisystem granulomatous inflammation. Although clinical trial data and subsequent real-world experience support dupilumab as a highly effective therapy for eosinophilic esophagitis, close monitoring for development of adverse symptoms following initiation remains paramount.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
